Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2026-05-15 4:25 pm Purchase | 2026-03-31 | 13G | LEXEO THERAPEUTICS INC LXEO | Paradigm BioCapital Advisors LP | 6,184,134 8.300% | 1,420,936 (+29.83%) | Filing History |
| 2026-05-15 06:23 am Sale | 2026-03-31 | 13G | LEXEO THERAPEUTICS INC LXEO | Balyasny Asset Management L.P. | 7,176,144 9.690% | -45,411 (-0.63%) | Filing History |
| 2026-04-13 5:03 pm Purchase | 2026-04-06 | 13G | LEXEO THERAPEUTICS INC LXEO | Suvretta Capital Management, LLC | 5,674,778 7.700% | 5,674,778 (New Position) | Filing History |
| 2026-03-27 10:16 am Sale | 2026-03-13 | 13G | LEXEO THERAPEUTICS INC LXEO | VANGUARD GROUP INC | 0 0.000% | -3,894,310 (Position Closed) | Filing History |
| 2026-02-17 4:38 pm Purchase | 2025-12-31 | 13G | LEXEO THERAPEUTICS INC LXEO | Citadel Advisors LLC | 5,498,219 7.400% | 164,107 (+3.08%) | Filing History |
| 2026-02-17 4:02 pm Purchase | 2025-12-31 | 13G | LEXEO THERAPEUTICS INC LXEO | Paradigm BioCapital Advisors LP | 4,763,198 6.500% | 1,091,199 (+29.72%) | Filing History |
| 2026-02-17 06:39 am Purchase | 2025-12-31 | 13G | LEXEO THERAPEUTICS INC LXEO | Balyasny Asset Management L.P. | 7,221,555 9.890% | 1,826,834 (+33.86%) | Filing History |
| 2026-02-13 5:33 pm Purchase | 2025-12-31 | 13G | LEXEO THERAPEUTICS INC LXEO | Frazier Life Sciences Public Fund, L.P. | 3,698,271 5.100% | 624,804 (+20.33%) | Filing History |
| 2026-01-30 2:18 pm Purchase | 2025-12-31 | 13G | LEXEO THERAPEUTICS INC LXEO | VANGUARD GROUP INC | 3,894,310 5.330% | 3,894,310 (New Position) | Filing History |
| 2026-01-29 7:58 pm Purchase | 2026-01-22 | 13G | LEXEO THERAPEUTICS INC LXEO | Affinity Asset Advisors, LLC | 5,217,660 7.100% | 965,655 (+22.71%) | Filing History |
| 2026-01-21 12:30 pm Purchase | 2025-12-31 | 13G | LEXEO THERAPEUTICS INC LXEO | BlackRock, Inc. BLK | 4,885,814 6.700% | 2,717,370 (+125.31%) | Filing History |
| 2025-12-08 11:45 am Purchase | 2025-11-28 | 13G | LEXEO THERAPEUTICS INC LXEO | JANUS HENDERSON GROUP PLC JHG | 7,291,434 9.990% | 1,185,907 (+19.42%) | Filing History |
| 2025-11-20 4:30 pm Purchase | 2025-11-13 | 13G | LEXEO THERAPEUTICS INC LXEO | Paradigm BioCapital Advisors LP | 3,671,999 5.000% | 3,671,999 (New Position) | Filing History |
| 2025-11-14 4:17 pm Unchanged | 2025-09-30 | 13G | LEXEO THERAPEUTICS INC LXEO | Longitude Capital Partners IV, LLC | 2,765,381 3.800% | 0 (Unchanged) | Filing History |
| 2025-11-14 4:00 pm Purchase | 2025-09-30 | 13G | LEXEO THERAPEUTICS INC LXEO | Vestal Point Capital, LP | 4,117,302 7.500% | 889,141 (+27.54%) | Filing History |
| 2025-11-14 12:49 pm Purchase | 2025-09-30 | 13G | LEXEO THERAPEUTICS INC LXEO | JANUS HENDERSON GROUP PLC JHG | 6,105,527 11.300% | 2,421,144 (+65.71%) | Filing History |
| 2025-11-14 06:04 am Sale | 2025-09-30 | 13G | LEXEO THERAPEUTICS INC LXEO | Balyasny Asset Management L.P. | 5,394,721 9.990% | -2,950,930 (-35.36%) | Filing History |
| 2025-11-07 4:42 pm Sale | 2025-09-30 | 13G | LEXEO THERAPEUTICS INC LXEO | Integrated Core Strategies (US) LLC | 2,313,642 3.200% | -522,650 (-18.43%) | Filing History |
| 2025-10-27 4:07 pm Purchase | 2025-10-20 | 13G | LEXEO THERAPEUTICS INC LXEO | RA CAPITAL MANAGEMENT L.P. | 5,000,000 6.900% | 5,000,000 (New Position) | Filing History |
| 2025-10-17 6:13 pm Purchase | 2025-09-30 | 13G | LEXEO THERAPEUTICS INC LXEO | BlackRock, Inc. BLK | 2,168,444 4.000% | 346,478 (+19.02%) | Filing History |